Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08860360.0Aexternal-prioritypatent/EP2240490B1/en
Application filed by Takeda Pharmaceutical Company LimitedfiledCriticalTakeda Pharmaceutical Company Limited
Publication of CY1114796T1publicationCriticalpatent/CY1114796T1/en
Ενώσεις 1- ή 2-υποκατεστημένης (6aR,9aS)-3-(φαινυλαμινο)-5-6a,7,8,9,9a-εξαϋδρο-5-μεθυλο-κυκλοπεντ[4,5]ιμιδαζο[1,2-a]πυραζολο[4,3-e]πυριμιδιν-4(1Η ή 2Η) όνης του τύπου (Ι), διεργασίες για την παραγωγή τους, η χρήση τους ως φαρμακευτικές ουσίες και φαρμακευτικές συνθέσεις που τις περιέχουν.Compounds of 1- or 2-substituted (6aR, 9aS) -3- (phenylamino) -5-6a, 7,8,9,9a-hexahydro-5-methyl-cyclopent [4,5] imidazo [1,2-a ] pyrazolo [4,3-e] pyrimidin-4 (1H or 2H) alone of formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions containing them.
Compounds derived from imidazo [1,2-a] pyrazine; pharmaceutical composition; and use of the compounds as protein kinase inhibitors in the treatment of cancer.
pyrido(2.3-f)quinoxaline-8-carboxylic acid derivatives and their isomeric pyrido(2.3-g)quinoxalines processfor their preparation and their use as potential antibactrial compounds
Compounds derived from cyclopenta [d] pyrimidine inhibitors of the kinase akt; Preparation process; pharmaceutical kit; pharmaceutical composition and use in the treatment of inflammatory, hyperproliferative, cardiovascular, neurodegenerative diseases, among others.